This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Antidepressant Efficacy and Tolerability of the Selective Norepinephrine Reuptake Inhibitor Reboxetine: A Review

Article Abstract

Reboxetine is a unique selective norepinephrine reuptake inhibitor (NRI) with proven antidepressantefficacy in pharmacologic and biochemical tests predictive of antidepressant properties. Comprehensiveclinical trials, including 8 placebo-controlled and/or active treatment-controlled studies, plus4 open studies, have assessed the short-term and long-term efficacy and tolerability of reboxetine inpatients with major depressive disorders and dysthymia. Results from a total of 690 patients whoentered 5 open or placebo-controlled studies are summarized in this paper. Four hundred forty-ninepatients with a diagnosis of either major depressive disorder or dysthymia were treated with reboxetinein these clinical studies of 4 weeks’ to 12 months’ duration. In a 6-week placebo-controlledstudy, clinically significant improvement (≥ 50% reduction in Hamilton Rating Scale for Depressiontotal score) was observed at last assessment in 74% of reboxetine-treated patients compared with 20%of patients in the placebo group. Similar results were observed in the 6-week run-in phases of the 3long-term studies, where the efficacy of reboxetine was maintained over the 12-month study period.Reboxetine was well tolerated; adverse events reported were mainly mild to moderate in severity, andthere were no clinically significant changes in vital signs or laboratory parameters. The first in itsclass, reboxetine, a selective NRI, will provide a valuable addition to the existing armamentarium ofagents used in the treatment of depression.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 59

Quick Links: Depression (MDD)